MHRA updates GCP inspections page and issues non-OECD MAD data guidance
MHRA published final guidance on 4 November 2026 on using non-clinical data generated outside the OECD MAD system in UK trial applications, including an enhanced pathway for some first-in-human trials. It also updated its GCP inspections page on 6 November 2026, with a 30-day deadline for inspection dossiers.
This update covers two MHRA publications from early November 2026: new guidance on non-clinical data generated outside the OECD Mutual Acceptance of Data (MAD) system, and an updated page on good clinical practice (GCP) inspections.
It matters most to sponsors whose trial applications rely on non-clinical safety data from test facilities outside OECD MAD, especially first-in-human oncology trials. It also matters to any sponsor that could be asked for a GCP inspection dossier.
- UKPublished 4 November 2026
Final guidance on non-OECD MAD non-clinical data in UK trial applications
Source: MHRA →On 4 November 2026 MHRA published final guidance on how non-clinical data generated outside the OECD MAD framework can support UK clinical trial authorisation applications. It sets out an Enhanced Non-Clinical Assessment Pathway, initially for first-in-human trials in advanced oncology or other life-threatening conditions. MHRA must confirm eligibility before submission. The guidance also adds sponsor expectations on test facility contracts, due diligence and what to include in the application. A related MHRA news story says the guidance does not change the standards expected for pivotal non-clinical safety data.
What it means for sponsors
Check whether any of your non-clinical data came from a test facility outside OECD MAD. This includes facilities in OECD countries that are not covered by a national GLP monitoring programme. A claim of GLP compliance does not give the same assurance. If your trial may qualify for the enhanced pathway, seek MHRA eligibility confirmation before you submit. MHRA encourages early engagement. Read the guidance in full to see what it expects on contracts, due diligence and application content. Applications that do not qualify can still go through the standard route and will be considered case by case.
- UKPublished 4 November 2026
MHRA plans inspections of non-clinical test facilities
Source: MHRA →MHRA's news story of 4 November 2026 announces a strategic, risk-based programme of inspections of non-clinical test facilities that are frequently named in UK clinical trial applications. MHRA says the findings will inform future assessments. It also says its approach will evolve with regulatory experience and inspection outcomes.
What it means for sponsors
If you use test facilities outside OECD MAD, expect that they may come under MHRA scrutiny. Make sure your contracts and oversight of those facilities are in good order. Keep an eye on MHRA updates, as the approach may change.
- UKPublished 6 November 2026
MHRA GCP inspections page updated, with a new infringement notice
Source: MHRA →MHRA updated its GCP inspections guidance page on 6 November 2026. The update adds a new infringement notice, RC ALS, which concerns an unauthorised trial started without authorisation or an ethics opinion. The page also says that when MHRA notifies an organisation that it is being considered for inspection, it will request a GCP inspection dossier and a clinical trials spreadsheet, to be provided within 30 days. A separate dossier template and spreadsheet are provided for computerised systems.
What it means for sponsors
Never start a trial without both authorisation and an ethics opinion. Make sure you can assemble a dossier and trial spreadsheet within 30 days of a request, using the MHRA templates. If your organisation supplies or relies on trial-specific computerised systems, check which dossier version applies. Read the full page for the other points it covers, including expectations on access to the trial master file.
Get regulatory updates in your inbox
An email whenever clinical trial regulation changes, explaining what it means for sponsors. If nothing changes in a month, a short note instead. Nothing else.
We'll only use your address to send these updates. Unsubscribe from any email. See our privacy notice.
Do these changes affect your SOPs?
We check every change against the procedures it touches, so you don't have to.
A reply from a person, usually within one business day.